Trial · NCT05500807
Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A
NCT05500807, Phase 1, Recruiting, Bleeding and Clotting Disorders Institute Peoria, Illinois
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A. Trials, record NCT05500807. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05500807
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A
- NCT number
- NCT05500807
- Status
- Recruiting
- Phases
- Phase 1
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Bleeding and Clotting Disorders Institute Peoria, Illinois
- Conditions
- Von Willebrand Disease, Type 3, Concomitant VWD and Hemophilia
- Interventions
- Emicizumab
- First posted
- 2022-08-15
- Last updated
- 2026-04-03
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Emicizumab is efficacious for prophylaxis in severe VWD & concomitant VWD/hemophilia A | 18 months | Establish bleed occurrence during treatment evaluated through descriptive statistical analysis to determine proof of principle |
| Primary | Emicizumab is safe for prophylaxis in severe VWD & concomitant VWD/Hemophilia A | 18 months | Collection of AE's, hypersensitivity reactions, thrombotic events during treatment |
| Secondary | Reduced treatment burden vs VWF/FVIII prophylaxis | 18 months | \# of infusions and methods of infusions collected during study |
| Secondary | Decreased bleed occurrence | 12 months | Evaluate historical ABR with on demand or prophy prior to study treatment |
| Secondary | Diminish bleed severity | 18 months | Collection of bleed data prior to study entry and throughout study treatment |
| Other | Improve health related QOL in study participants | 18 months | Collection of HRQOL PRO's |
| Other | Reduce product use for spontaneous or traumatic bleeds | 18 months | Bleed \& treatment logs collecting product use prior to study entry and throughout study treatment |
| Other | Reduce product use during surgery | 18 months | Bleed \& treatment logs collect information for any surgical procedure while on study, blood loss, hemostatic efficacy and concentrate consumption. |
| Other | Reduce self-reported treatment burden for HMB | 18 months | Bleed \& treatment logs collect treatment information prior to and during study for HMB including antifibrinolytics, concentrates and hormonal therapies. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers19
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05500807
GET https://conductscience.org/api/trials/v1/NCT05500807/registered